0
Signin
countryflagUS

18889881171

AAPL 190.415 0.3663% MSFT 422.65 -0.1016% GOOG 175.36 0.8512% GOOGL 174.14 0.9449% AMZN 185.71 -0.1505% NVDA 943.46 -0.3001% META 473.555 -1.6582% TSLA 174.87 0.5058% TSM 154.06 -0.977% LLY 776.1758 -1.3779% V 280.145 -0.2972% AVGO 1436.4972 0.0228% JPM 204.205 1.0366% UNH 522.225 0.9033% NVO 133.03 -1.2105% WMT 63.485 6.109% LVMUY 170.79 -0.2511% XOM 117.87 -0.5988% LVMHF 855.728 -0.1473% MA 461.6867 0.805%

NLS Pharmaceutics AG

Healthcare US NLSPW

0.0399USD
-0.0031(7.21%)

Last update at 2024-05-16T15:24:00Z

Day Range

0.040.04
LowHigh

52 Week Range

0.040.29
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -16.49568M -11.94608M -2.86144M -5.44715M -5.14677M
Minority interest - - - - -
Net income -17.41818M -11.99689M -3.09513M -6.26686M -5.14677M
Selling general administrative 6.51M 5.94M 2.20M 2.49M 2.01M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.01M 0.01M - - -
Ebit -15.48236M -11.86062M -2.29937M -4.19704M -2.81963M
Ebitda -15.46091M -11.86789M -2.62773M -4.26248M -3.44886M
Depreciation and amortization 0.02M -0.00727M -0.32837M -0.06545M -0.62923M
Non operating income net other - - - - -
Operating income -15.48236M -11.86062M -2.29937M -4.19704M -3.44886M
Other operating expenses 15.48M 11.86M 2.30M 4.20M 3.45M
Interest expense 0.10M 0.07M 0.23M 0.82M 1.07M
Tax provision - - - - -
Interest income - - 0.56M 0.89M 1.07M
Net interest income -0.10087M -0.06813M -0.23370M -0.81971M -1.06867M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.92M 0.05M 0.23M 0.82M 1.70M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 15.48M 11.86M 2.30M 4.20M 3.45M
Cost of revenue - - - - -
Total other income expense net -1.01332M -0.08546M -0.56207M -1.25011M -0.62923M
Discontinued operations - - - - -
Net income from continuing ops -16.49568M -11.94608M -2.86144M -5.44715M -5.14677M
Net income applicable to common shares - - -2.86144M -5.44715M -5.14677M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 9.28M 5.76M 1.21M 0.70M 0.15M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 291.95M 35.05M - 0.08M
Total liab 6.00M 5.22M 10.20M 6.87M 8.96M
Total stockholder equity 3.28M 0.54M -8.98406M -6.17095M -8.81371M
Deferred long term liab - - - - -
Other current liab 0.99M 0.67M -2498.54288M 0.84M 0.58M
Common stock 0.67M 0.34M 0.15M 0.15M 0.13M
Capital stock 0.67M 0.34M 0.15M 0.15M 0.13M
Retained earnings -58.20146M -41.70578M -29.75970M -26.89826M -21.45112M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.95M 0.26M -
Cash 8.95M 5.43M 0.09M 0.22M 0.00668M
Cash and equivalents - - - - -
Total current liabilities 3.36M 2.40M 7.20M 4.04M 2.41M
Current deferred revenue - 2499.97M 2499.97M - -
Net debt -8.94840M -5.43120M 1.99M 0.62M 7.09M
Short term debt - -2499.96900M 1.77M 0.69M 0.71M
Short long term debt - - 1.77M 0.69M 0.71M
Short long term debt total - - 2.08M 0.84M 7.09M
Other stockholder equity 60.86M 42.06M 20.65M 20.60M 12.52M
Property plant equipment - - - - -
Total current assets 9.25M 5.72M 0.20M 0.38M 0.09M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.04M 0.04M 0.06M 0.11M -
Long term debt - - 0.31M 0.15M 6.39M
Inventory - -291.70060M -35.00421M - -
Accounts payable 2.37M 1.74M 4.01M 2.51M 1.13M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.05079M -0.15174M -0.01938M -0.01870M -0.01125M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.01M 0.01M 1.01M - 0.06M
Deferred long term asset charges - - - - -
Non current assets total 0.03M 0.04M 1.01M 0.31M 0.06M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00000M -0.03956M - - -
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities 17.40M 20.34M 0.50M 0.41M 0.56M
Change to operating activities - - - - -
Net income -16.49568M -11.94608M -2.86144M -5.44714M -5.14677M
Change in cash 3.52M 5.34M -0.12656M 0.21M -2.17625M
Begin period cash flow 5.43M 0.09M 0.22M 0.00668M 2.18M
End period cash flow 8.95M 5.43M 0.09M 0.22M 0.00668M
Total cash from operating activities -13.87937M -14.93604M -0.72939M -0.19001M -2.73280M
Issuance of capital stock 9.22M 14.55M - - 0.00000M
Depreciation 0.01M 0.01M 72.19M - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 8.88M 8.00M 0.50M 0.41M 0.56M
Change to netincome - - - - -
Capital expenditures 0.00000M 0.04M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.63M -3.16652M 2.06M 4.12M 0.67M
Stock based compensation 0.02M - - - -
Other non cash items 0.96M 0.17M -72.12007M 1.14M 1.75M
Free cash flow -13.87937M -14.97560M -0.72939M -0.19001M -2.73280M

Fundamentals

  • Previous Close 0.04
  • Market Cap37.77M
  • Volume1046
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.33241M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
NLSPW
NLS Pharmaceutics AG		 -0.0031 7.21% 0.04 - - - -
NVO
Novo Nordisk A/S		 -1.63 1.21% 133.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.57 0.43% 132.69 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.20 0.27% 438.69 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 1.03 1.09% 96.00 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

NLS Pharmaceutics AG

Alter Postplatz 2, Stans, Switzerland, 6370

Key Executives

Name Title Year Born
Mr. Alexander Zwyer Co-Founder, CEO & Director 1970
Mr. Robert Dickey IV, M.B.A. Interim Chief Financial Officer 1956
Dr. Silvia Panigone Interim Chief Operating Officer 1972
Mr. Mehdi Tafti Ph.D. Interim Chief Scientific Officer 1959
Dr. Christian C. Wenger L.L.M., Dr. iur., Ph.D., LL.M. Gen. Counsel 1964
Ms. Sharon Keys Head of Regulatory Affairs NA
Dr. Sandy Eisen M.D. Interim Chief Medical Officer 1956
Mr. Herve Girsault M.A., M.B.A., MA, MBA Interim Chief Bus. Officer 1960
Dr. Geert Mayer M.D. Interim Chief Devel. Officer 1949

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).